Jonathan Kil, MD
CEO & CMO
CEO & CMO
Dr. Kil has led the R&D strategy and financings for SPI. He has served as the principal investigator on several NIH and Dept. of Defense (DoD) awards, and serves as Chief Medical Officer. Dr. Kil studied auditory neuroscience at UC Irvine where he graduated with honors and received the Ralph W Gerard Award for outstanding research. He began his MD/PhD studies at Georgetown University where he was an ARCS Scholar and received a Clinical Prize for his work on traumatic injury to the cochlea. He continued his graduate studies in Neuroscience and Medicine at UVA, where he received the Winn Scholarship in Otolaryngology.
Dr. Kil completed his NIH funded post-doctoral research on ototoxicity at the University of Washington, and in 1998, he co-founded Otogene, the first inner ear biotechnology company. As President and CEO, he transitioned its basic research involving p27Kip1 technology into a pre-clinical regeneration platform. In 2002, he co-founded SPI to translate some of his discoveries in to investigational products for the treatment of inner ear disease. He is a recognized leader in inner ear drug development and has served as an advisor to the DoD’s Hearing Center of Excellence since 2012.
President & CSO
Dr. Lynch has led the discovery and scientific programs at SPI and serves as our Chief Science Officer. He completed his BS in Genetics at UC Davis and his PhD at UC Berkeley, where he mapped the first human gene for non-syndromic sensorineural hearing loss, DFNA1. During his post-doctoral studies at the University of Washington, he worked collaboratively to clone and characterize DFNA1 and DFNA15, and the cancer genes BRCA1 and PTEN. As an Assistant Professor in the Division of Medical Genetics at the UW, he served on the 1999 Strategic Planning Committee of the NIH, Division of Deafness and Communication Disorders. In 2001, Dr. Lynch was the CSO of Otogene and lead their pre-clinical research efforts involving auditory hair cell regeneration. In 2002, he co-founded SPI to further discover novel drug targets within the mammalian inner ear that are responsible for acute and chronic sensorineural disease.
Paul has led research and development operations at several top pharmaceutical and biotechnology companies including Merck, Schering-Plough, UCB, and Galleon. He has worked across several therapeutic indications including first-in-class neurology-targeted therapeutics. Paul has provided operational leadership to over 30 first-in-man INDs and contributed to 6 NDAs. He is a globally experienced (US, EU, Asia, and Latin America) drug development leader with a persistent history of quickly progressing novel therapies from discovery to development. Paul majored in biochemistry at The Ohio State University, and received an MBA from the University of Liverpool in International Business.
Dr. Wall is an accomplished leader in specialty pharmaceuticals, best exemplified by his successes while at Alcon Laboratories where he launched their Otolaryngology R&D efforts. Dr. Wall led the development and commercialization of Ciprodex® Otic Suspension for the treatment of acute otitis externa and acute otitis media in patients with tympanostomy tubes which remains the #1 eardrop prescribed by otolaryngologists and pediatricians in the U.S. He also led the development and commercialization of Patanase® Nasal Spray for the treatment of allergic rhinitis in children (including pediatric exclusivity) and adults (#1 intranasal antihistamine prescribed by U.S. pediatricians). Further, he led development for other otic products such as XTORO® and formulation improvements for CIPRO® HC, and significantly contributed to development of ophthalmic products such as AZOPT®, BETOPTIC® S, CILOXAN®, IOPIDINE®, PATADAY®, PATANOL®, TRAVATAN®, VEXOL® and VIGAMOX®. He has directed the conduct of over 40 clinical trials, phase 1-4. Dr. Wall earned his Ph.D. in Medicinal Chemistry from the University of Mississippi School of Pharmacy and has completed Harvard Business School’s Advanced Management Program. (Trademarks are property of their owners.)
Mr. Ashley has held key management positions in several biotechnology and medical device companies. He was the President of Beckman Instruments’ Clinical Division, which was acquired by Smith Kline in 1983. From 1983-1985, he was the President of Genetic Systems, one of Seattle’s first biotechnology companies, that was acquired by Bristol-Myers in 1984. He is currently the Chairman of Copernicus Therapeutics, a DNA-based drug delivery company in Cleveland, Ohio.
Dr. Kawasaki is the Founder, President and CEO of Accium Biosciences, a Seattle company focused on atomic mass spectroscopy. From 1981-1985, he was the first scientist and the Chair of the Science Board at ZymoGenetics, Inc. From 1989-1998, he was the Founder, President, and CEO of Aptein, Inc., which was acquired by Cambridge Antibody Technology. He was previously the Founder, President and CEO at Catch, Inc., which sold its homocysteine assay to Axis-Shield.
Dr. Kil was appointed by King County Executive Dow Constantine to serve on the Board of Trustees at Harborview Medical Center/UW. He serves as the Board President of the Academy for Precision Learning, an independent K-12 autism inclusion school in Seattle. He also serves as a Trustee of the Bertschi School, an independent elementary school in Seattle.
Dr. Lynch serves as Board member is the immediate past President for the Lake Forest Park Civic Club, a 501c4 organization serves over 800 member families and individuals in the Lake Forest Park Washington community. Under his 4 years as President, he brought transparency and process to the forefront. Led initiatives to revitalize the membership and improve the facilities, and helped to increase membership over 30% and revenues over 50%. He also serves as a Board member and Secretary of Chance Fashion, a 501c3 organization that serves the fashion community in Washington state by providing training and opportunities for individuals interested in the fashion industry to learn the various roles involved in producing a fashion show with real life experience. Chance Fashion has produced a fashion show every month in the Seattle area for over 8 years and is expanding the model to other cities in the USA. In 2017, he founded the software company, CoSensei and serves a member of their Board and as its President.
Dr. Guyer is the Co-Founder, Chairman, and CEO of Ophthotech (NASDAQ:OPHT) and has lead its financing strategy since its inception in 2007. In addition to taking OPHT public, Dr. Guyer co-founded and served as CEO and Director at Eyetech Pharmaceuticals (NASDAQ:EYET), where he led the company through private and public financings totaling over $400 million. David oversaw the development of Macugen, the first FDA-approved anti-VEGF treatment for wet AMD. EYET reached a peak market capitalization of approximately $2 billion as was later sold to OSI Pharmaceuticals in 2005. Prior Opthotech, David was a Venture Partner at SV Life Sciences and Professor and Chairman of Ophthalmology at New York University School of Medicine.
Dr. Beutler, a recipient of several major honors including the Nobel Prize for Physiology and Medicine in 2011, discovered some of the key molecules and pathways involved in Tumor Necrosis Factor (TNF) mediated inflammation. This work led to development of several TNF-alpha inhibitors, including Enbrel, the leading biologic drug for the treatment of Rheumatoid Arthritis. Dr. Beutler is currently a Regental Professor and Director of the Center for Genetics of Host Defense at the University of Texas Southwestern Medical Center and is member of the US National Academy of Sciences.
Dr. Roberts is the former Director of the Basic Sciences Division at Fred Hutchinson Cancer Research Center. He is an expert in cell growth and division, and a past collaborator on SPI’s regenerative technology involving p27Kip1. Dr. Roberts is currently the Founder and CSO for MatrixGenetics, a Seattle biotechnology company focused on biofuels.
Mr. Robins is the Co-Founder, President and CEO of Adaptive Biotechnologies in Seattle, WA. He has lead Adaptive’s development and finance strategy since its inception in 2008. Mr. Robins has held executive-level positions in real estate, investing, and medical technology, and has been recognized as one of the most successful biotechnology executives. In 2012, he was a “40 Under 40” Seattle Leaders honoree. In 2015, he was honored as one of Goldman Sachs 100 Most Intriguing Entrepreneurs of the Year. In 2016, Mr. Robins was also a finalist for the Ernst & Young Entrepreneur Of The Year® Award in the Pacific Northwest.
Dr. Schein founded U.S. Bioscience, a pharmaceutical company focused on cancer and AIDS. While serving as Chairman and CEO he brought three products, Ethyol, Hexalen and Neutrexin, through regulatory approval in the US and Europe. Dr. Schein has served as President of the American Society of Clinical Oncology and Chaired the Food and Drug Administration’s Oncologic Drugs Advisory Committee. He is a recipient of numerous scientific and medical awards including the Harvey W. Wiley Medal from the FDA and the Wainwright Award for Excellence in Medical Education.
Dr. Wendel has made significant contributions to the understanding of selenoproteins such as glutathione peroxidase and novel selenoorganic compounds such as ebselen. He co-founded the Interfaculty Center for Pharmacogenomics and Pharma Research at the University of Tübingen. From 2009 to 2014, he lead collaborative research teams involving patients, clinicians, and scientists to advance basic discoveries to translational medicine. Dr. Wendel is a member of the SAB for the Berlin-Brandenburger Center for Regenerative Therapies and was Chair of Biochemical Pharmacology at the University of Konstanz from 1988 to 2008.
Dr. Miller is a Professor of Medicine, Microbiology, Immunology and Genome Sciences at the University of Washington. He has been the Director of the NIAID Northwest Research Center for Excellence in Biodefense and Emerging Infectious Diseases since its inception in 2003 and of the University of Washington Enteric Research Investigative Center of NIAID since 2010. He is the past Director of the Cystic Fibrosis Research and Development Program at the U W. He received his B.A. from John Hopkins University in 1975 and M.D. in 1979 from Baylor College of Medicine and was an Intern, Resident, Fellow, Assistant and Associate Professor at the Massachusetts General Hospital and Harvard Medical School. His research training was in the laboratories of Dr. Dyann Wirth (Harvard School of Public Health, molecular parasitology) and Dr. John Mekalanos (Harvard Medical School, bacterial pathogenesis).